These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 29514608)
21. Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina. Abreu RM; Froufe HJ; Queiroz MJ; Ferreira IC Chem Biol Drug Des; 2012 Apr; 79(4):530-4. PubMed ID: 22188672 [TBL] [Abstract][Full Text] [Related]
22. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient. Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971 [TBL] [Abstract][Full Text] [Related]
23. Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products. Vásquez AF; Reyes Muñoz A; Duitama J; González Barrios A J Biomol Struct Dyn; 2021 Jun; 39(9):3285-3299. PubMed ID: 32362218 [TBL] [Abstract][Full Text] [Related]
24. Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer. Rampogu S; Baek A; Bavi R; Son M; Cao GP; Kumar R; Park C; Zeb A; Rana RM; Park SJ; Lee KW IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1663-1674. PubMed ID: 30334765 [TBL] [Abstract][Full Text] [Related]
25. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach. Konidala KK; Bommu UD; Pabbaraju N J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316 [TBL] [Abstract][Full Text] [Related]
26. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations. Saxena S; Abdullah M; Sriram D; Guruprasad L J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866 [TBL] [Abstract][Full Text] [Related]
27. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors. Zhang G; Ren Y Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939 [TBL] [Abstract][Full Text] [Related]
28. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. Sangande F; Julianti E; Tjahjono DH Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664 [TBL] [Abstract][Full Text] [Related]
29. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT. Matore BW; Roy PP; Singh J J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656 [TBL] [Abstract][Full Text] [Related]
30. Pharmacophore modeling coupled with molecular dynamic simulation approach to identify new leads for meprin-β metalloprotease. Chaudhuri A; Hudait N; Chakraborty SS Comput Biol Chem; 2019 Jun; 80():292-306. PubMed ID: 31054542 [TBL] [Abstract][Full Text] [Related]
31. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation. Bavi R; Kumar R; Choi L; Woo Lee K PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025 [TBL] [Abstract][Full Text] [Related]
32. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
33. Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors. Zhang Y; Zhang M; Wang Y; Fan Y; Chen X; Yang Y; Hua Y; Xie W; Lu T; Tang W; Chen Y; Liu H J Biomol Struct Dyn; 2020 Jun; 38(9):2559-2574. PubMed ID: 31232191 [TBL] [Abstract][Full Text] [Related]
34. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation. Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071 [TBL] [Abstract][Full Text] [Related]
36. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches. Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340 [TBL] [Abstract][Full Text] [Related]
37. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase. Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109 [TBL] [Abstract][Full Text] [Related]
38. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415 [TBL] [Abstract][Full Text] [Related]
39. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach. Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799 [TBL] [Abstract][Full Text] [Related]
40. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors. Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]